Business Wire

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

Jaa

Veristat, a full-service Clinical Research Organization (CRO), announced today that it has partnered with Triumph Research Intelligence (TRI), a global leader providing technology and solutions for centralized and risk-based monitoring (RBM) to improve clinical trial quality and compliance.

Earlier this year, the US Food and Drug Administration (FDA) issued a new guidance known as the International Council for Harmonization’s (ICH’s) Guideline for Good Clinical Practice (GCP) or ICH GCP E6(R2), that addresses critical key aspects of clinical trial inefficiency and complexity. This specifically includes trial design, management and oversight, patient safety, data integrity, and computer system validation.

“I’m excited to work with TRI to deliver enhanced services to our sponsors who are embracing RBM and centralized monitoring in their studies. The ability to quickly identify areas of quality risk and their causes will allow us to target our onsite monitoring activities effectively and focus our efforts on areas to improve data quality and ensure patient safety. Additionally, we will ensure compliance with regulatory authorities,” said Shaheen Limbada, SVP Global Clinical Operations at Veristat.

The FDA guidance encourages the adoption of risk-based quality practices that have the potential to support improved efficiency and patient safety, data quality and cost savings for clinical trials. This prompted a rapidly increasing demand for centralized and risk-based monitoring solutions from both clinical research organizations (CROs) and sponsors. TRI’s RBM technology platform optimizes trial quality by improving data reliability, patient safety, and operational efficiency.

“We’re delighted to partner with Veristat as they are a leading CRO with a global reputation for quality and excellence. In a world of big data, it’s still people that make decisions. Using our technology platform will enable Veristat and their sponsors to make better-informed decisions faster,” said Duncan Hall, CEO and Founder of TRI.

For more information, visit http://www.veristat.com and http://www.tritrials.com.

About Veristat

Veristat is a clinical research partner focused on supporting biopharmaceutical firms as they advance their therapies through the clinical development and regulatory submission process. Our work delivers meaningful clinical impact and our regulatory submission expertise is unrivaled in our industry. Veristat teams have worked on over 70 regulatory submission projects that have resulted in more than 40 submission approvals to date from various regulatory agencies around the world. Over the last 5 years alone, nearly 8% of new molecular entities (NMEs) approved by the FDA were supported by Veristat teams. Veristat aims to propel even the most complex submissions to successful regulatory conclusions so that new therapies become available to improve and save lives. For more information, visit http://www.veristat.com.

About TRI

Triumph Research Intelligence (TRI) is a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials. It is based in Cambridge, UK, and Raleigh, North Carolina in the United States. Over 10% of failed NDA submissions are due to data quality and cost the industry hundreds of millions of dollars each year. TRI was founded in 2011 by CEO Duncan Hall to directly address this issue. TRIs products, solutions and services are designed to optimize clinical trial quality by improving data reliability and at the same time increase patient safety and operational efficiency.

Contact information

Veristat:
Gillian Dellacioppa, +1 508-306-6336
Marketing Director
gillian.dellacioppa@veristat.com
or
TRI:
Neil Watkins, +44 (07710) 420477
Head of Marketing
neil.watkins@tritrials.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07Tiedote

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 10:58Tiedote

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs

Kalray Joins Autoware Foundation as Founding Premium Member14.12.2018 10:18Tiedote

Kalray (Euronext Growth Paris – ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined the Autoware Foundation as a founding premium member. The formation of Autoware was formally announced on December 10, 2018 with a mission of facilitating the deployment of Autoware open-source projects enabling self-driving mobility. The Autoware Foundation creates synergies between corporate development and academic research, enabling autonomous driving technology for everyone. "We are glad to have the presence of Kalray as a premium member of the Autoware Foundation. Having highly efficient hardware solutions supporting autonomous driving software is instrumental to boost the deployment of Autoware in the market!" said Shinpei Kato, member of the Board of Directors for Autoware. Autonomous driving demands massive processing power, low power consumption and bulletproof safety and security to handle critical functions like AI processing, acceleration of perception

IDEMIA Provides Subscription Management Platform to dtac in Thailand to Offer eSIM Connected Watches to All Its Subscribers.14.12.2018 06:30Tiedote

IDEMIA, the global leader in Augmented Identity, has been selected by dtac, the leading mobile operator in Thailand, to offer connectivity on eSIM connected watches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005934/en/ Credits : IDEMIA IDEMIA’s Subscription Management platform (or remote SIM provisioning) is the technology that remotely connects the embedded SIM of a smartwatch to dtac’s network without inserting a physical SIM card. Indeed, the IDEMIA Subscription Manager is a server which securely manages the lifecycle of mobile subscriptions and profiles for eSIM-ready consumer devices and wearables. This solution is compliant with the latest GSMA (Global System for Mobile Communications Association) standards to ensure global interoperability and, thanks to the scalability of the platform, the operator will be able to serve up to millions of customers during peak times. dtac subscribers now have the possibilit

CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer13.12.2018 20:46Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include rucaparib as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. EC approval is anticipated in the first quarter of 2019. Once approved, Rubraca’s indication will expand beyond its initial Marketing Authorization in Europe granted in May 2018 for adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum

Dole Food Company Sells Fresh Cut Business in Sweden and Finland13.12.2018 20:00Tiedote

Dole Food Company, Inc., announced today an agreement to sell Saba Fresh Cuts AB and Saba Fresh Cuts OY to BAMA International. Saba Fresh Cuts AB—with production facility in Helsingborg Sweden—and Saba Fresh Cuts OY—with production facility in Espoo Finland—are producers of washed and ready-to-eat salads. The companies prepare and sell various fresh-cut salads and vegetables to the retail and foodservice industry in Sweden, Denmark, Finland, Germany and the Baltic States. The sale of Saba Fresh Cuts AB was a necessary condition of the European Commission’s approval of the investment by Total Produce into Dole in July 2018. “I am very pleased with the outcome of this sale in meeting the EU’s requirement,” said Mr. Johan Linden, President and Chief Executive Officer of Dole Food Company, “and I am confident that Saba Fresh Cuts will be in good hands under BAMA’s ownership.” "We are pleased to announce this agreement with Dole for Saba Fresh Cuts. Convenience products and ready-to-eat sal

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme